about
Tesaglitazar, a dual PPAR{alpha}/{gamma} agonist, ameliorates glucose and lipid intolerance in obese Zucker ratsVitamin C may have similar beneficial effects to Gemfibrozil on serum high-density lipoprotein-cholesterol in type 2 diabetic patientsDiabetes: mellitus or lipidus?How does blood glucose control with insulin save lives in intensive care?Prevalence and pattern of dyslipidemia in Nepalese individuals with type 2 diabetesMetabolic effects of fluvastatin extended release 80 mg and atorvastatin 20 mg in patients with type 2 diabetes mellitus and low serum high-density lipoprotein cholesterol levels: a 4-month, prospective, open-label, randomized, blinded-end point (prHepatic triacylglycerol synthesis and secretion: DGAT2 as the link between glycaemia and triglyceridaemia.Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins.Influence of peroxisome proliferator-activated receptor alpha agonists on the intracellular turnover and secretion of apolipoprotein (Apo) B-100 and ApoB-48.Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes.
P2860
Q28572510-2579A7CC-5882-4F6F-BB7B-6BD662B63546Q34349093-91E5FD47-6297-42AF-BF5B-26C88FFAFAB8Q35103998-8C2877E1-7FDE-4B92-B9CA-3A713BF66915Q35936472-60E4F9B4-19C1-49D2-B6F3-4FB8EC018F95Q36334878-6DDDD6A0-C0D6-4045-A76A-BE09C2F526B2Q37660996-333E11A9-75CF-4A1C-9085-B702C4F44F5BQ38089264-380B9A10-9B85-4BF8-BFD8-96D694FD5F8FQ39320400-9968759B-BAA5-44BE-9E93-8EF5B720ED08Q40741210-8003FA34-6B25-430E-B897-0DC671508B3FQ44613028-05B93F22-B548-4E72-8395-FE903DF988CA
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Pathogenesis of dyslipidemia in type 2 diabetes.
@ast
Pathogenesis of dyslipidemia in type 2 diabetes.
@en
Pathogenesis of dyslipidemia in type 2 diabetes.
@nl
type
label
Pathogenesis of dyslipidemia in type 2 diabetes.
@ast
Pathogenesis of dyslipidemia in type 2 diabetes.
@en
Pathogenesis of dyslipidemia in type 2 diabetes.
@nl
prefLabel
Pathogenesis of dyslipidemia in type 2 diabetes.
@ast
Pathogenesis of dyslipidemia in type 2 diabetes.
@en
Pathogenesis of dyslipidemia in type 2 diabetes.
@nl
P356
P1476
Pathogenesis of dyslipidemia in type 2 diabetes.
@en
P2093
Taskinen MR
P304
P356
10.1055/S-2001-18580
P478
109 Suppl 2
P577
2001-01-01T00:00:00Z